JACC Advances, Journal Year: 2024, Volume and Issue: 4(1), P. 101459 - 101459
Published: Dec. 12, 2024
Estimation of long-term risk for cardiovascular events using the SMART (Secondary Manifestations Arterial Disease) score can be potentially valuable in devising mitigation strategies.
Language: Английский
JACC Asia, Journal Year: 2024, Volume and Issue: 4(7), P. 517 - 518
Published: June 12, 2024
Language: Английский
Citations
2
American Journal of Preventive Cardiology, Journal Year: 2024, Volume and Issue: 19, P. 100702 - 100702
Published: June 23, 2024
The inhibition of intestinal cholesterol absorption by ezetimibe improves outcomes after myocardial infarction (MI), yet real-world data on is scarce. We studied the usage and association with outcome MI. Consecutive MI patients in Finland (2010-2018) were retrospectively (N = 57,505; 65% men; mean age 69 years). study collected from national registries. median follow-up was 4.5 (IQR 2.8-7.1) years. Between-group differences adjusted for using multivariable regression. Ezetimibe use competing risk analyses. cumulative incidence 3.7% at 90 days, 13.4% 5 years, 19.8% 10 Younger one strongest predictors (adj.sHR 6.67; CI 5.88-7.69 aged <60 vs ≥80 Women more likely to during than men. average proportion 6.8%. (11.7% discontinued 43.6% follow-up. Patients early therapy had lower all-cause mortality (33.6% 45.1%; adj.HR 0.77; 0.69-0.86; P<0.0001). Early associated irrespective sex, age, atrial fibrillation, diabetes, heart failure, malignancy, revascularization, or statin use. Ongoing a time-dependent analysis (adj.HR 0.53; 0.48-0.59; death MI, its therapeutic limited, discontinuation frequent.
Language: Английский
Citations
2
Journal of Functional Foods, Journal Year: 2024, Volume and Issue: 120, P. 106379 - 106379
Published: Aug. 6, 2024
Language: Английский
Citations
2
Published: Aug. 8, 2024
Reducing levels of low-density-lipoprotein-cholesterol (LDL-C) below recommended thresholds is a core component cardiovascular prevention strategies. We hypothesized that the addition bempedoic acid to patients already on statin-ezetimibe therapy was more effective than titrating statin dose in reducing LDL-C. The study enrolled 120 at high risk, and with LDL-C above 70 mg/dl. They were randomly divided two groups: (BA) group, taking plus ezitimibe, titration (ST) group including who doubled statin. At 12-weeks, BA presented greater significant decrease compared ST (-22.9% vs 7.5% p 0.002). Total-cholesterol decreased significantly (-14.8% vs-4.7% ; 0.013) No between-groups changes HDL triglycerides occurred. 12 weeks number reached lower mg/dl 38 (63%) versus 22 (37%) (between 0.034). In LDL lowering effect similar between atorvastatin rosuvastatin. side effects occurred during follow up period. conclusion, Bempedoic statin/ezetimibe combined treatment doubling increased reaching goal.
Language: Английский
Citations
1
International Journal of Smart and Nano Materials, Journal Year: 2024, Volume and Issue: 15(3), P. 610 - 651
Published: July 2, 2024
Atherosclerosis is a severe cardiovascular disease followed by the accumulation of atherosclerotic plaques within lumen blood vessels resulting in reduced flow thus initiating series events. Conventional therapies for atherosclerosis encounter multiple challenges, especially difficulty precisely concentrating certain affected regions and potential unwanted side effects. Consequently, scientists are focused on developing nanoformulations diagnosis therapy. Peptide-based nanomedicines improve conventional offering improved structural therapeutic stability enabling target-specific delivery. Their inherent biocompatibility biodegradability additionally render them desirable materials intended vivo use. This review manuscript aims to provide an in-depth overview peptide-based atherosclerosis, focusing targeted cells like endothelial cells, macrophages, monocytes their interaction with different plaque components. Moreover, also highlights latest progress multimodal techniques provides comprehensive limitations associated practical implementation.
Language: Английский
Citations
1
Pharmaceuticals, Journal Year: 2024, Volume and Issue: 17(12), P. 1581 - 1581
Published: Nov. 25, 2024
This paper investigates the therapeutic use of PCSK9 inhibitors, particularly Evolocumab, as monoclonal antibodies for treatment atherosclerosis based on recent literature reviews. is an outstanding example a breakthrough in medical science, with advancements understanding its biological function driving substantial progress treatment. Atherosclerotic cardiovascular disease (ASCVD) leading global cause mortality, imposing financial burdens healthcare systems. Elevated low-density lipoprotein cholesterol (LDL-C), modifiable risk factor, plays pivotal role development ASCVD. Emerging treatments such inhibitors are now being introduced to combat this issue, goal reducing ASCVD by directly targeting LDL-C levels. discovery highlighted potential inhibit PCSK9, thereby enhancing receptor activity. led Alirocumab and Evolocumab which typically reduce levels approximately 50%. research underscores importance treating ASCVD, drawing evidence from various randomized controlled trials FOURIER, ODYSSEY OUTCOMES, VESALIUS-CV. These have also shown that effective safe several disorders. therefore useful patients who do not reach their target when highest doses statins or very high cannot tolerate at all.
Language: Английский
Citations
1
Diagnostics, Journal Year: 2024, Volume and Issue: 14(12), P. 1241 - 1241
Published: June 13, 2024
Low-density lipoprotein cholesterol (LDL-C), which makes up about 70% of the in blood, is critical formation arteriosclerotic plaques, increasing risk heart disease. LDL-C levels are estimated using Friedewald, Martin and Sampson equations, though they have limitations with high triglycerides. Our aim to compare effectiveness these equations versus ultracentrifugation technique individuals without dyslipidemia identify precision. There were 113 participants, 59 healthy controls 54 dyslipidemic patients. Samples collected after fasting. was equations. The purified LDL-C, ultracentrifugated dialysized control group vs. patients coronary artery disease (CAD) showed differences age, HDL-C, triglycerides glucose non-HDL-C (
Language: Английский
Citations
0
PLoS ONE, Journal Year: 2024, Volume and Issue: 19(8), P. e0309470 - e0309470
Published: Aug. 22, 2024
Low-Density Lipoprotein (LDL) cholesterol is one of the main target for cardiovascular (CV) prevention and therapy. In last years, Proprotein Convertase Subtilisin–Kexin type 9 inhibitors (PCSK9-i) has emerged as a key therapeutic to lower LDL were introduced CV events. Recently (June 2022) Italian Medicines Agency (AIFA) modified eligibility criteria use PCSK9-i. We designed an observational study estimate prevalence eligible subjects evaluate effectiveness PCSK9-i applying Target Trial Emulation (TTE) approach based on Electronic Health Records (EHR). Subjects meeting identified from July 2017 (when became available) December 2020. Outcomes all-cause death first hospitalization. Among subjects, we those treated at date prescription. Inverse Probability Treatment Weights (IPTW) estimated including demographic clinical covariates, history treatment with statins month/year date. Competing risk models weighted cohorts used derive Average Effect (ATE) Conditional (CATE) in subgroups interest. Out 1976 161 (8%) received Treated individuals slightly younger, predominantly male, had more severe conditions, often statin compared untreated subjects. The latter exhibited higher non-CV comorbidities. A significant absolute relative reduction hospitalization was observed. confirmed CATE analysis. PCSk9-i prescribed minority Within TTE framework, analysis association between events, aligning findings randomized trials (RCTs). our study, provided protection specifically against death, expanding upon evidence RCTs that primarily focused composite outcomes.
Language: Английский
Citations
0
Journal of Cardiovascular Development and Disease, Journal Year: 2024, Volume and Issue: 11(9), P. 286 - 286
Published: Sept. 14, 2024
Reducing levels of low-density lipoprotein cholesterol (LDL-C) below recommended thresholds is a core component cardiovascular prevention strategies. We hypothesized that the addition bempedoic acid to patients already on statin–ezetimibe therapy was more effective than titrating statin dose in reducing LDL-C. The study enrolled 120 at high risk and with LDL-C above 70 mg/dL. They were randomly divided into two groups: (BA) group, taking plus ezitimibe, titration (ST) including who doubled statin. At 12 weeks, BA group presented significant decrease compared ST (−22.9% vs. 7.5% p 0.002). total decreased significantly (−14.8% vs.−4.7%; 0.013) No between-group changes HDL triglycerides occurred. number reached lower mg/dL 38 (63%) versus 22 (37%) (between groups, 0.034). In LDL-lowering effect similar between atorvastatin rosuvastatin. side effects occurred during follow up period. conclusion, combined treatment doubling increased reaching goal.
Language: Английский
Citations
0
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy, Journal Year: 2024, Volume and Issue: 44(11), P. 861 - 869
Published: Oct. 23, 2024
Abstract Background Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) have been shown to improve cardiovascular outcomes by reducing low‐density lipoprotein cholesterol (LDL‐C). However, sex differences in the efficacy of evolocumab remain unclear. This study aimed investigate using real‐world data. Method Data were collected from First Affiliated Hospital Guangxi Medical University. A total 416 eligible patients selected 1463 treated with for secondary prevention. Clinical data, including individual characteristics and lipids profiles, recorded. Propensity score matching (PSM) was used control potential confounders, covariates age, body mass index, smoking status, diabetes. All participants propensity‐matched 1:1 female versus male a match tolerance 0.02. The females males compared PSM‐adjusted analysis. Results In PSM analysis, significant difference found relative percentage reduction LDL‐C between (−42.7% vs. −54.4%, p < 0.001). addition, absolute lower (interquartile range: −1.5 [−2.2, −0.8] mmol/L −1.9 [−2.5, −1.0] mmol/L, = 0.018). rate target attainment than after treatment (21.6% 39.8%, 0.009). Conclusion These results suggest that better response term females.
Language: Английский
Citations
0